Abstract:
The present study was addressed to formulate and evaluate LOLA-loaded poly (DLlactic-co-glycolic acid) (PLGA) nanoparticles (NPs) prepared by the double emulsion solvent evaporation method and characterizes their properties. LOrnithine-L-Aspartate (LOLA) has been used in the treatment of liver diseases like Hepatic encephalopathy, having shorter biological half-life of 40 minute, thus it is a good candidate for the formulation of sustained release dosage form. The experiments were performed based on various variables; effect of poly-vinylalcohol (PVA) concentration, amount of LOLA, amount of PLGA, the volume ratio of the inner water phase and the intermediate phase, and effect of sonication time. The prepared NPs were evaluated based on their physicochemical characteristics like, particle size, zeta-potential, scanning electron microscopy (SEM). Optimized batch was produced particle size 323 nm with respect to negative zeta potential. SEM study reveals that particles were spherical in shaped and had a smooth surface. Fourier transform infrared (FTIR) and differential scanning calorimetry (DSC) study did not show any interaction between drug and polymer. In-vitro release studies were found to be zero order and followed higuchi model. In-vitro release of optimized formulation had shown 36.67% of drug release after 5 days providing sustain release of drug. It is therefore concluded that PLGA nanoparticles are capable of delivering LOLA over prolonged period achieving a sustained delivery of LOLA, thus making it a potential candidate for hepatic disease.

Keywords: L-ornithine-L-aspartate, PLGA, Nanoparticles, In-vitro Release.